HilleVax is focused on developing vaccines against Norovirus. Norovirus is the most common viral cause of acute gastroenteritis worldwide and causes 200,000 deaths annually. It can cause illness at any age, but young children and older adults are at most risk. To prevent illness from infection, HilleVax is assembling experience in vaccine development, clinical trial operations, manufacturing and commercialization. HilleVax’s current lead product vaccine is HIL-214, a bivalent virus-like particle vaccine for active immunization against norovirus. HIL-214 is in clinical trials for all age-groups from infants to older adults, with current data showing the vaccine to be well tolerated and clinical proof of concept in preventing acute gastroenteritis.

<p>HilleVax is focused on developing vaccines against Norovirus. Norovirus is the most common viral cause of acute gastroenteritis worldwide and causes 200,000 deaths annually. It can cause illness at any age, but young children and older adults are at most risk. To prevent illness from infection, HilleVax is assembling experience in vaccine development, clinical trial operations, manufacturing and commercialization. HilleVax’s current lead product vaccine is HIL-214, a bivalent virus-like particle vaccine for active immunization against norovirus. HIL-214 is in clinical trials for all age-groups from infants to older adults, with current data showing the vaccine to be well tolerated and clinical proof of concept in preventing acute gastroenteritis.</p>


HilleVax

Founded: 2021
Location: Boston, MA
Employee range: 11 - 50
Clinical stage: Clin2
Therapy area: Norovirus (adult)
Drug types: INF, VAC, PED, GER
Lead product: HIL-214
Funding: $200M IPO Apr 2022; $135M Sep 2021

Drug notes:

About:

Jobs: